Fortune journal of health sciences · 2026
Rapid Preparation of Carrier-Free Self-Assembled Aqueous Nanoformulations of Ten BCS Class II Drugs, Propofol, and Hydroxyapatite Using FAST Nanotechnology.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hsu Stephen, Yu Hongfang, Philip Archith, Mouna Amani, Marshall Brendan, Dickinson Douglas
Аннотация
Poor aqueous solubility remains a major barrier to the development, repurposing, and improved delivery of clinically important small-molecule drugs. This formulation problem is especially relevant to Biopharmaceutics Classification System (BCS) Class II drugs, for which dissolution rather than membrane permeability may limit absorption and translational testing. Here, we evaluated Facilitated Self-Assembling Technology (FAST) as a rapid, carrier-free aqueous nanoformulation platform for ten representative BCS Class II drugs, propofol, and Omyadent HA100 hydroxyapatite as an inorganic oral-care material. FAST generated nanoscale aqueous suspensions across the drug panel, with negative zeta potentials and no visible macroscopic precipitation, sedimentation, aggregation, phase separation, or foam formation under the visual assessment conditions. Transmission electron microscopy of propofol, itraconazole, rifampin, and HA100 suspensions supported diverse nanoscale morphologies, including rounded particles, heterogeneous particle clusters, and irregular mineral clusters. Itraconazole showed coexisting rod-like electron-dense structures consistent with possible crystalline/nanocrystalline material and rounded nanoscale particles, supporting future investigation of morphology-controlled reformulation. FAST-processed HA100 showed nanoscale mineral clusters, indicating that FAST may extend beyond hydrophobic organic drugs to inorganic materials. This study establishes a formulation-feasibility framework and supports further evaluation of FAST as a clean, rapid, carrier-free platform for early formulation screening, value-added reformulation of approved drugs, AI-assisted drug discovery, topical/local delivery concepts, and future oral-care applications, subject to determination of improved dissolution, pharmacokinetics, bioavailability, or efficacy.